Clinical Trials Sponsored by NLS Pharmaceutics

Total 25920 results

Basilea Pharmaceutica

Available

Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations

Intrahepatic Cholangiocarcinoma
Basilea Pharmaceutica

Completed

Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy

Acute Myeloid Leukemia

Germany
Basilea Pharmaceutica

Completed

Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Hand Dermatoses

Germany
Basilea Pharmaceutica

Completed

Alitretinoin in the Treatment of Chronic Hand Eczema

Eczema

France, Germany
Basilea Pharmaceutica

Completed

Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis

Hand Dermatoses

Germany
Vesale Pharmaceutica

Completed

Dietary Supplementation of Lactogyn in Women With Bacterial Vaginosis

Bacterial Vaginosis

Ukraine
Janssen Pharmaceutica

Completed

A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis

Psoriasis | Plaque

Brazil
Janssen Pharmaceutica

Withdrawn

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Janssen Pharmaceutica

Withdrawn

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Prostate Neoplasms
Janssen Pharmaceutica

Withdrawn

A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis
Janssen Pharmaceutica

Withdrawn

A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation

Chronic Constipation

Philippines
Basilea Pharmaceutica

Withdrawn

Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia

Bacteremia
Janssen Pharmaceutica

Completed

An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis

Osteoarthritis

Philippines
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Basilea Pharmaceutica

Completed

Ceftobiprole in Hospital Acquired Pneumonia

Pneumonia
Basilea Pharmaceutica

Terminated

A Study of Ceftobiprole in Patients With Fever and Neutropenia.

Neutropenia | Fever | Gram-positive Bacterial Infections | Pseudomonas Infection
Basilea Pharmaceutica

Completed

Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

ICU

United States, Belgium, Spain, Israel, Korea, Republic of, Canada
Basilea Pharmaceutica

Completed

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Skin Diseases, Infectious | Staphylococcal Skin Infections | Skin Diseases, Bacterial
Basilea Pharmaceutica

Completed

Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Skin Diseases, Infectious | Staphylococcal Skin Infections | Skin Diseases, Bacterial
ISA Pharmaceuticals
Regeneron Pharmaceuticals

Active, not recruiting

A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Squamous Cell Carcinoma of the Oropharynx

United States, Israel, Belgium, Germany, Spain, United Kingdom, Italy, France, Czechia
Portola Pharmaceuticals

Completed

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

Bleeding

United States
Jazz Pharmaceuticals
GW Pharmaceuticals

Terminated

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Rett Syndrome | RTT

United States, Canada, Italy, Spain, United Kingdom, Australia
Alexion Pharmaceuticals
Portola Pharmaceuticals

Completed

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Follicular Lymphoma (FL/Indolent NHL) | Aggressive NHL (a NHL) | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | T-cell Lymphoma (PTCL and CTCL) | B-cell Non Hodgkin Lymphoma (NHL)

United States
Basilea Pharmaceutica

Recruiting

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Neonatal Sepsis

United States, Latvia, Lithuania, Poland, Slovakia, Bulgaria, Estonia, Germany
Basilea Pharmaceutica

Not yet recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis

Candidemia | Candidiasis, Invasive
Basilea Pharmaceutica

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
Basilea Pharmaceutica

Completed

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

Candidemia

Germany, United States, Israel, Spain, Belgium
Basilea Pharmaceutica

Available

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

Invasive Fungal Infections
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Basilea Pharmaceutica

Completed

Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Hand Dermatoses

Poland, Germany, Canada
Basilea Pharmaceutica

Completed

An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors

Solid Organ Tumors

United Kingdom
Basilea Pharmaceutica

Completed

Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma

Neoplasms

Switzerland
Janssen Pharmaceutica

Withdrawn

A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients

Human Immunodeficiency Virus-Type 1
Janssen Pharmaceutica

Withdrawn

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

Moderate to Severe Chronic Non-cancer Pain
Janssen Pharmaceutica

Terminated

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Pain
Janssen Pharmaceutica

Completed

A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections

Intraabdominal Infections | Pneumonia, Bacterial | Urinary Tract Infection | Nosocomial Infection

Philippines
Janssen Pharmaceutica

Completed

An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain

Osteoarthritis | Low Back Pain

Philippines
Janssen Pharmaceutica

Completed

An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis

Vulva; Candidiasis
Basilea Pharmaceutica

Completed

Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers

Streptococcal Infections | Staphylococcal Skin Infections
Basilea Pharmaceutica

Completed

Effect of Ceftobiprole on Human Intestinal Microflora

Drug Resistance | Antimicrobial Agent | Cephalosporins
Basilea Pharmaceutica

Terminated

Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia

Ventilator Associated Pneumonia
Basilea Pharmaceutica

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
Basilea Pharmaceutica

Completed

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Invasive Fungal Infections

United States
Basilea Pharmaceutica

Completed

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

Fungal Infection

Netherlands
Basilea Pharmaceutica

Active, not recruiting

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in People With Hepatic Dysfunction.

Hepatic Impairment

United States
Basilea Pharmaceutica

Terminated

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)

Gastric Adenocarcinoma

Spain, United States, Korea, Republic of, Belgium, Russian Federation, United Kingdom, Italy, France, Turkey, Germany, Poland, Brazil, Australia, Argentina, Chile
Basilea Pharmaceutica

Completed

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)

Intrahepatic Cholangiocarcinoma | Combined Hepatocellular and Cholangiocarcinoma

Canada, United States, Spain, Belgium, Italy, Korea, Republic of, Germany, Switzerland, France, United Kingdom, Ireland
Basilea Pharmaceutica

Completed

Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)

Urothelial Carcinoma

United Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
Basilea Pharmaceutica

Completed

Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Community-acquired Pneumonia (CAP) | Hospital-acquired Pneumonia (HAP)

Bulgaria, Hungary, Georgia, Romania

3

Subscribe